Ligand director granted RSUs and stock options
Ligand Pharmaceuticals director Jason Haas received equity awards as part of board compensation.
Rhea-AI Filing Summary
Ligand Pharmaceuticals director Jason Haas received equity awards as part of board compensation. He acquired 836 restricted stock units, each representing one share of common stock, bringing his direct common stock holdings to 7,442 shares. He also received a non-qualified stock option for 2,938 shares at an exercise price of $237 per share, expiring on June 5, 2036. Both the RSUs and options fully vest on the earlier of the company’s next annual stockholder meeting following the grant date or the first anniversary of the June 5, 2026 grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 3,774 shares
Grant/Award
2 txns
Insider
Haas Jason
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 2,938 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 836 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 2,938 contracts (Direct);
Common Stock — 7,442 shares (Direct)
Footnotes (2)
- F1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
- F2. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
Key Figures
RSUs granted: 836 units
Common shares after grant: 7,442 shares
Options granted: 2,938 options
+2 more
5 metrics
RSUs granted
836 units
Restricted stock units granted June 5, 2026
Common shares after grant
7,442 shares
Direct common stock holdings following RSU grant
Options granted
2,938 options
Non-qualified stock option granted June 5, 2026
Option exercise price
$237 per share
Strike price for non-qualified stock option
Option expiration
June 5, 2036
Expiration date of non-qualified stock option
Key Terms
restricted stock units ("RSUs"), Non-Qualified Stock Option, annual meeting, expiration date
4 terms
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy) with an exercise price of 237.0000"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
annual meeting financial
"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026."
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
expiration date financial
"Non-Qualified Stock Option ... with an expiration date of 2036-06-05"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Ligand Pharmaceuticals (LGND) director Jason Haas report in this Form 4?
Jason Haas reported receiving equity compensation awards. He acquired 836 restricted stock units and a non-qualified stock option for 2,938 shares, both granted on June 5, 2026 as part of his service on Ligand’s board of directors.
What are the key terms of Jason Haas’s new stock option at Ligand Pharmaceuticals (LGND)?
Haas received a non-qualified stock option for 2,938 shares of Ligand common stock. The option has an exercise price of $237 per share and expires on June 5, 2036, providing long-term equity exposure tied to his board service.
When do Jason Haas’s new restricted stock units in Ligand Pharmaceuticals (LGND) vest?
The 836 restricted stock units fully vest on the earlier of two dates. Vesting occurs at the next annual Ligand stockholders’ meeting following the June 5, 2026 grant or on the first anniversary of that grant date.
Are Jason Haas’s Ligand Pharmaceuticals (LGND) equity awards part of a purchase or compensation?
The awards represent compensation rather than an open-market purchase. Both the 836 restricted stock units and the option for 2,938 shares were granted by Ligand’s board of directors at its annual meeting on June 5, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
